Published in Medical Letter on the CDC and FDA, February 20th, 2005
This patent, when issued, protects EOquin for use in the treatment of superficial bladder cancer and will not expire until November 2022.
Spectrum Pharmaceuticals announced the completion of enrollment in EOquin multi-center phase 2 trial for refractory superficial bladder cancer on January 6, 2005. The company plans to present phase 2 data on EOquin at the European Association of Urologists...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA